Literature DB >> 24582120

Modified retroperitoneoscopic renal pedicle lymphatic disconnection for intractable chyluria.

Bianjiang Liu1, Jiexiu Zhang1, Jie Li1, Pu Li1, Zhijian Han1, Ninghong Song1, Lixin Hua1, Zengjun Wang2, Ming Gu1, Changjun Ying1.   

Abstract

INTRODUCTION: To describe a modified retroperitoneoscopic renal pedicle lymphatic disconnection (MRRPLD) and to compare the efficacy and safety of MRRPLD with traditional retroperitoneoscopic renal pedicle lymphatic disconnection (RRPLD). TECHNICAL CONSIDERATIONS: From September 2008 to July 2012, RRPLD and MRRPLD were performed respectively on 18 and 14 patients at our center. Comparison was conducted including operative time, intraoperative blood loss, postoperative time of bed rest, hospital stay, postoperative urine chyle test, and complications. All operations were completed without conversion to open surgery. The mean operative time, intraoperative blood loss, postoperative time of bed rest, and hospital stay from MRRPLD group were all decreased compared with data from RRPLD group. There was significant difference in operative time, postoperative time of bed rest, and hospital stay (P <.05). Complications occurred only in 1 patient receiving RRPLD. Chyluria disappeared in all patients after the operation. No recurrence was observed during the follow-up.
CONCLUSION: MRRPLD has a good effect and safety for chyluria. It is a simpler, more minimally invasive, and more economic surgical therapy compared with traditional RRPLD.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24582120     DOI: 10.1016/j.urology.2013.12.030

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  1 in total

1.  It is unnecessary to completely mobilize the kidney in retroperitoneoscopic renal pedicle lymphatic disconnection for intractable chyluria.

Authors:  Tao Zhang; Jinyou Wang; Dexin Yu; Jiaxing Ma; Haoqiang Shi; Liangkuan Bi; Dongdong Xie; Yi Wang; Jie Min
Journal:  Int Urol Nephrol       Date:  2016-06-30       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.